← Leaderboards
Javeed Iqbal
University Of Nebraska Medical Center
$5,566,166
Attributed
$9,778,435
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,778,435 · 7
By mechanism
R01$4,327,696 · 2
P01$2,062,800 · 1
U01$1,827,310 · 1
UH3$864,147 · 1
UH2$397,085 · 1
R41$299,397 · 1
Top collaborators
- Wing C. Chan14 shared
- Muhammed Murtaza5 shared
- Robert Zygmunt Orlowski4 shared
- Joo Song2 shared
- Stephan Wade Morris1 shared
Most similar at University Of Nebraska Medical Center
Same institution · by research overlap
- Wing C. Chan$16,090,658
- Julie Marie Vose$3,263,070
Others in their field
Other Emerging Leaders on “T-Cell Lymphoma”
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$39,889,328
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$20,250,477
- Cecilia Larocca · Brigham And Women'S Hospital$3,995,479
- Marco Ruella · University Of Pennsylvania$3,783,970
- Lisa Giulino Roth · Weill Medical Coll Of Cornell Univ$3,726,722
- Yevgeny Brudno · North Carolina State University Raleigh$3,552,576
Research focus
T-Cell LymphomaMolecularDiagnosisPeripheralGeneticLymphomaNon-Hodgkin&AposGene ExpressionTumorSamplingS LymphomaGene Expression ProfilingSubgroupNovel TherapeuticsClassificationMorphologyGenesCell LineParaffin EmbeddingLesionImmunophenotypingFormalinPrognosticSpecimen
Grant awards (25)
Cooperative role of TET2 and IDH2 mutations in angioimmunoblastic T-cell lymphomagenesis$488,400
R01 · FY2025 · CA · contact PI
Role of Heat Shock Protein 70 as a Mediator and Therapeutic Target in T-cell Lymphomas$483,912
R01 · FY2025 · CA
Pre-analytical variables of bioanalytes affecting the accuracy of PTCL diagnostic and prognostic genetic signatures$367,321
U01 · FY2025 · CA · contact PI
Cooperative role of TET2 and IDH2 mutations in angioimmunoblastic T-cell lymphomagenesis$463,981
R01 · FY2024 · CA · contact PI
Role of Heat Shock Protein 70 as a Mediator and Therapeutic Target in T-cell Lymphomas$459,716
R01 · FY2024 · CA
Pre-analytical variables of bioanalytes affecting the accuracy of PTCL diagnostic and prognostic genetic signatures$348,939
U01 · FY2024 · CA · contact PI
Cooperative role of TET2 and IDH2 mutations in angioimmunoblastic T-cell lymphomagenesis$478,632
R01 · FY2023 · CA · contact PI
Role of Heat Shock Protein 70 as a Mediator and Therapeutic Target in T-cell Lymphomas$474,235
R01 · FY2023 · CA
Pre-analytical variables of bioanalytes affecting the accuracy of PTCL diagnostic and prognostic genetic signatures$359,942
U01 · FY2023 · CA · contact PI
Role of Heat Shock Protein 70 as a Mediator and Therapeutic Target in T-cell Lymphomas$499,410
R01 · FY2022 · CA
Cooperative role of TET2 and IDH2 mutations in angioimmunoblastic T-cell lymphomagenesis$478,632
R01 · FY2022 · CA · contact PI
Molecular Pathogenesis of Two Newly Defined Major Subgroups of PTCL$424,577
P01 · FY2022 · CA · contact PI
Pre-analytical variables of bioanalytes affecting the accuracy of PTCL diagnostic and prognostic genetic signatures$359,962
U01 · FY2022 · CA · contact PI
Cooperative role of TET2 and IDH2 mutations in angioimmunoblastic T-cell lymphomagenesis$500,778
R01 · FY2021 · CA · contact PI
Molecular Pathogenesis of Two Newly Defined Major Subgroups of PTCL$408,752
P01 · FY2021 · CA · contact PI
Pre-analytical variables of bioanalytes affecting the accuracy of PTCL diagnostic and prognostic genetic signatures$391,146
U01 · FY2021 · CA · contact PI
Molecular diagnostic and prognostic signatures for PTCL$246,546
UH3 · FY2021 · CA · contact PI
Molecular Pathogenesis of Two Newly Defined Major Subgroups of PTCL$403,141
P01 · FY2020 · CA · contact PI
Molecular diagnostic and prognostic signatures for PTCL$301,020
UH3 · FY2020 · CA · contact PI
Molecular Pathogenesis of Two Newly Defined Major Subgroups of PTCL$404,457
P01 · FY2019 · CA · contact PI
Molecular diagnostic and prognostic signatures for PTCL$316,581
UH3 · FY2019 · CA · contact PI
Molecular Pathogenesis of Two Newly Defined Major Subgroups of PTCL$421,873
P01 · FY2018 · CA · contact PI
Development of a Novel Clinical Diagnostic Assay for Peripheral T-cell Lymphoma (PTCL)$299,397
R41 · FY2018 · CA
Molecular diagnostic and prognostic signatures for PTCL$191,615
UH2 · FY2018 · CA · contact PI
Molecular diagnostic and prognostic signatures for PTCL$205,470
UH2 · FY2017 · CA · contact PI